Xenetic Biosciences, Inc.

For the period ended Dec 31, 2025. Filed Mar 12, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 12, 2026

XBIO$1.80-3.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Power of Attorney

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Xenetic Biosciences, Inc., hereby severally constitute and appoint James Parslow, our true and lawful attorney, with full power to him, to sign for us in our names in the capacities indicated below, all amendments to this report, and generally to do all things in our names and on our behalf in such capacities to enable Xenetic Biosciences, Inc. to comply with the provisions of the Securities Exchange Act of 1934, as amended, and all requirements of the Securities and Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated below on the 12th day of March, 2026.

Grigory Borisenko
Signature	Title(s)
/s/ JAMES PARSLOW	Interim Chief Executive Officer and Chief Financial Officer
James Parslow	(Principal Executive Officer and Principal Financial Officer and Principal Accounting Officer)
/s/ GRIGORY BORISENKO	Director
/s/ FIRDAUS JAL DASTOOR	Director
Firdaus Jal Dastoor
/s/ Dmitry Genkin	Director
Dmitry Genkin
/s/ ROGER KORNBERG	Director
Roger Kornberg
	Director
Moshe Mizrahy
/s/ ALEXEY VINOGRADOV	Director
Alexey Vinogradov

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.